Objectives: To compare the immediate and short-term (6 months) angiographic and clinical outcomes in patients with de-novo small vessel disease (SVD) treated with drug-coated balloon (DCB) versus drug-eluting stent (DES) Methods: Sixty patients underwent percutaneous coronary revascularization of SVD (reference vessel diameter <3 mm). They were randomly assigned in a 1:1 ratio to be treated with either: SeQuent® please Neo paclitaxel-eluting DCB (30 patients) or Xience Expedition Evorolimus-eluting DES (30 patients). Angiographic (using Quantitative Coronary Angiogram) and clinical outcomes (MACE) were was assessed immediately and at 6 months follow up. Results: Patients with DES had better immediate angiographic vessel wall expansion and acute lumen gain in comparison to the DCB (1.79 ± 0.21 mm vs 1.64 ± 0.20 mm, p= 0.006). At 6 months follow up, late lumen loss was significantly less in DCB group compared to DES (0.28 ± 0.29 mm vs. 0.42 ± 0.20 mm, p=0.04). However, late minimal lumen diameter (1.81 ± 0.27mm vs. 1.83 ± 0.18 mm, p=0.881), late diameter stenosis (26.3 ± 11.5% vs. 27.7 ± 7.9%, p= 0.584), and net lumen gain (1.35 ± 0.18 mm vs. 1.37 ± 0.15 mm, p= 0.79) were similar between both groups.
Background: Coronary bifurcation lesion is important subject in percutaneous coronary intervention (PCI). While much progress has been made in PCI facilities, bifurcation stenting is still has a lot of problems. Objective: The aim of this study was the usefulness of intravascular ultrasound (IVUS) to help in the prediction of occlusion of side branch (SB) after stenting the main vessel (MV) in bifurcation lesions. Patients and methods: The period of this study was from May 2019 to December 2020, and included 80 patients who were submitted for elective coronary angiography to the cardiology department at Maadi Military Hospital, and showed bifurcation lesions treated with provisional stenting using IVUS measurements. Results: This study included two groups according to the occlusion of SB after main vessel stenting .The 1st group had the patients with occlusion of SB (n= 18) and the 2nd group had the patients without occlusion of SB (n= 62). The thinner plaque of main vessel (MV) at junction position with SB, MV plaque area and diameter ratio of SB were the factors which could predict acute occlusion of SB after provisional stenting. Conclusion:In coronary bifurcation lesions, we can use intravascular ultrasound (IVUS) to help in the prediction of occlusion of SB after provisional stenting, and these predictors can help the operators to prepare the best strategy for treating bifurcation lesions.
Objectives: To compare the immediate and short-term (6 months) angiographic and clinical outcomes in patients with de-novo small vessel disease (SVD) treated with drug-coated balloon (DCB) versus drug-eluting stent (DES) Methods: Sixty patients underwent percutaneous coronary revascularization of SVD (reference vessel diameter <3 mm). They were randomly assigned in a 1:1 ratio to be treated with either: SeQuent® please Neo paclitaxel-eluting DCB (30 patients) or Xience Expedition Evorolimus-eluting DES (30 patients). Angiographic (using Quantitative Coronary Angiogram) and clinical outcomes (MACE) were was assessed immediately and at 6 months follow up. Results: Patients with DES had better immediate angiographic vessel wall expansion and acute lumen gain in comparison to the DCB (1.79 ± 0.21 mm vs 1.64 ± 0.20 mm, p= 0.006). At 6 months follow up, late lumen loss was significantly less in DCB group compared to DES (0.28 ± 0.29 mm vs. 0.42 ± 0.20 mm, p=0.04). However, late minimal lumen diameter (1.81 ± 0.27mm vs. 1.83 ± 0.18 mm, p=0.881), late diameter stenosis (26.3 ± 11.5% vs. 27.7 ± 7.9%, p= 0.584), and net lumen gain (1.35 ± 0.18 mm vs. 1.37 ± 0.15 mm, p= 0.79) were similar between both groups.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.